GHRP-2 (Pralmorelin)

GHRP-2 operates through a dual-site neurohormonal mechanism centered on GHSR1a (ghrelin receptor) activation — a G-protein coupled receptor expressed in the hypothalamic arcuate nucleus, pituitary somatotrophs, and peripheral metabolic tissues. Its pharmacological profile is meaningfully distinct from both exogenous recombinant GH and GHRH analogues, offering a physiologically patterned GH pulse rather than sustained supraphysiologic GH elevation.

Hypothalamic and Pituitary GH Secretagogue Activity

GHRP-2 stimulates GH release through two convergent mechanisms at the pituitary:

• GHSR1a agonism in pituitary somatotrophs directly triggers GH secretion via protein kinase C (PKC) and cyclic AMP (cAMP) intracellular signaling pathways, with GH release caused by Ca²⁺ influx through voltage-gated calcium channels
• Partial GHRH receptor co-activation has been demonstrated in bovine and ovine pituitary models, suggesting GHRP-2 may act synergistically with endogenous GHRH to amplify GH pulse amplitude beyond what GHSR1a activation alone would achieve
• Hypothalamic somatostatin suppression: GHRP-2 reduces the inhibitory somatostatin tone at the hypothalamus, disinhibiting somatotroph GH release — a mechanism that complements direct pituitary stimulation
• The combination of direct pituitary stimulation and hypothalamic somatostatin suppression produces reliable, reproducible GH pulses following subcutaneous or intravenous administration, which underpins its clinical utility as a GH provocation test agent in Japan
• GH secretion is dose-dependent across the studied range, with peak plasma GH levels reliably achieved approximately 15–60 minutes post-administration

Ghrelin Pathway Effects: Appetite and Metabolism

Because GHRP-2 is a synthetic ghrelin mimetic, its receptor binding produces ghrelin-associated downstream effects beyond GH secretion:

• Appetite stimulation: GHRP-2, like ghrelin itself, reliably induces hunger and increases food intake in humans following acute administration — making it of potential research interest in cachexia, anorexia, and wasting-associated conditions
• Gastric motility modulation: GHRP-2 has been demonstrated to stimulate upper gastrointestinal contractile activity in animal models, consistent with ghrelin’s known prokinetic gastrointestinal effects
• Glucagon and cortisol/ACTH co-secretion: GHSR1a activation by GHRP-2 also stimulates adrenocorticotropic hormone (ACTH) release, producing transient cortisol elevation — a class effect shared across GHRPs that has both clinical implications and adverse effect implications
• Anti-inflammatory signaling: Preclinical data in arthritic rat models demonstrated an anti-inflammatory effect of GHRP-2, attributed to ghrelin receptor-mediated modulation of inflammatory cytokine pathways — a property of uncertain clinical relevance in humans
• Insulin sensitivity interaction: GHRP-2 administration is associated with transient impairment of insulin sensitivity, consistent with the counter-regulatory metabolic effects of elevated GH and cortisol

Structural Pharmacology and Oral Bioavailability

GHRP-2’s chemical architecture directly informs its pharmacological behavior:

• The D-amino acid substitutions (D-Ala at position 1, D-β-naphthylalanine at position 2, D-Phe at position 4) confer resistance to proteolytic degradation by gastrointestinal and plasma peptidases — enabling oral bioavailability, a structural achievement uncommon among peptide-based drugs
• The β-naphthylalanine unnatural amino acid at position 2 is a key structural feature that enhances GHSR1a binding affinity while also, as acknowledged by the FDA, adding complexity to peptide characterization and quality control in manufacturing contexts
• Relative to GHRP-6 — its closest structural analogue — GHRP-2 produces a more potent GH response but somewhat less pronounced appetite stimulation, reflecting differential receptor engagement profiles despite shared core pharmacology
• Half-life following intravenous administration is short, in the range of minutes to low hours in plasma — supporting bolus-dosing models rather than continuous infusion for clinical applications

GHRP-2 has the most substantial clinical evidence base among the synthetic growth hormone-releasing peptides (GHRPs) as a class — reflecting its decades-long research history dating to its development at Tulane University and the progression of pralmorelin to regulatory approval in Japan. Evidence spans in vitro receptor pharmacology, preclinical animal studies, Phase 1 safety and pharmacokinetic trials, and multiple human randomized controlled trials (RCTs). It is important to note that the clinical evidence base for GHRP-2 is predominantly diagnostic (GH provocation testing) rather than therapeutic (long-term disease management), reflecting the compound’s current regulatory position.

Preclinical and Structural Evidence

• GHRP-2 was developed through systematic structure-activity optimization of a series of met-enkephalin analogues at Tulane University, ultimately identified as the lead compound for GHSR1a agonism with the best balance of GH-releasing potency, metabolic stability, and oral bioavailability
• Animal studies confirmed GHRP-2 acts on pituitary somatotrophs to increase cAMP concentration in a manner similar to GHRH, occurring even during blockade of Ca²⁺ influx — characterizing a dual intracellular signaling profile
• Preclinical models demonstrated GHRP-2 produced greater GH-releasing potency than GHRP-6 in equivalent-dose comparisons, establishing its relative position within the GHRP compound class
• Anti-inflammatory effects were demonstrated in arthritic rat models (2005, American Journal of Physiology — Endocrinology and Metabolism), attributed to ghrelin-pathway cytokine modulation, though human translation remains unvalidated

Phase 1 and Pharmacokinetic Studies

• Early Phase 1 studies confirmed GHRP-2’s GH-releasing activity in healthy human volunteers, characterizing the dose-response relationship and identifying peak GH at approximately 15–60 minutes post-dose
• GHRP-2 was demonstrated to transiently impair insulin sensitivity and elevate cortisol in certain dosing regimens — findings that established the hormonal co-secretion profile requiring monitoring in clinical application
• Pharmacokinetic characterization confirmed oral bioavailability, though subcutaneous and intravenous routes produce more reliable and higher-amplitude GH responses than oral dosing at equivalent doses
• Studies evaluating GHRP-2 during strenuous exercise (Medicine and Science in Sports and Exercise, 2000) documented the interaction between endogenous exercise-stimulated GHRH and exogenous GHRP-2, demonstrating synergistic GH amplification

Clinical Trials: GH Deficiency Diagnosis

Kojima et al. (Endocrine Journal, 2004) conducted pralmorelin testing specifically for GH deficiency diagnosis, providing the pivotal evidence supporting the Japan regulatory approval:

• GHRP-2 provocation reliably distinguished GHD patients from healthy controls through GH peak response — establishing its clinical utility as a GH stimulation test agent
• Results documented a consistent peak in GH levels approximately one hour post-GHRP-2 administration, with marginal efficacy decreases observed in certain populations, likely reflective of somatotroph reserve variability
• The test demonstrated sufficient sensitivity and specificity to support regulatory approval by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for single-dose diagnostic use

Hashimoto et al. (Clinical Endocrinology, 2002) conducted a dedicated clinical trial characterizing the GH-releasing effect of GHRP-2, contributing one of the anchor RCTs for the compound’s clinical evidence base. The study confirmed dose-dependent GH secretion and supported the 100 mcg intravenous dose used in Japanese clinical practice for GH stimulation testing.

Pediatric Growth Hormone Deficiency: Chronic Dosing Trial

Laron et al. (Journal of Clinical Endocrinology and Metabolism, 1998) examined the effects of eight months of chronic subcutaneous GHRP-2 administration at graded doses in prepubertal GHD children:

• Growth velocity was significantly higher during GHRP-2 treatment compared to both pre-treatment and post-treatment evaluation periods — the first human evidence of therapeutic growth-promoting efficacy from a GHRP
• No side effects or toxicities were observed during the eight-month treatment period, suggesting a favorable short-to-medium-term safety profile in the pediatric GHD population
• GH secretion was reliably stimulated throughout the treatment period without evidence of tachyphylaxis (receptor desensitization) at the doses studied — a clinically important finding distinguishing GHRP-2 from some earlier GHRP-class compounds
• These results positioned GHRP-2 as the most clinically validated GHRP for potential therapeutic applications in GHD, though no regulatory program for therapeutic approval has been advanced in the US or EU to date

Evidence Summary by Indication

Clinical Development

GHRP-2 is not the subject of any active clinical development program for new therapeutic indications in the United States or European Union as of May 2026:

• As a diagnostic agent, pralmorelin is approved and commercially available in Japan (Kaken Pharmaceutical) for single-dose intravenous GH stimulation testing in suspected GHD patients
• No NDA, BLA, or IND has been filed with the FDA for any therapeutic or diagnostic use of GHRP-2 in the United States
• No active Phase 2 or Phase 3 trials for therapeutic indications are registered in gov as of May 2026
• Research interest in GHRP-2 for cachexia, sarcopenia, and short bowel syndrome has been noted in the literature, but no sponsor has advanced a formal clinical development program beyond early-stage investigation

Regulatory Status

FDA (United States): GHRP-2 is not approved for any human therapeutic or diagnostic use in the United States. Its compounding status is specifically restricted:

• GHRP-2 (for injectable and nasal routes of administration) was placed on the FDA’s 503B Category 2 bulk drug substance list on September 29, 2023, citing the following identified safety risks: (1) risk of immunogenicity due to potential for aggregation and peptide-related impurities; (2) the presence of an unnatural amino acid (D-β-naphthylalanine) that adds complexity to peptide characterization; and (3) FDA awareness of serious adverse events in patients who received GHRP-2, including increased insulin requirement, death of critically ill study subjects, infection, and pancreatitis — though causality has not been established
• As of May 2026, GHRP-2 remains on the Category 2 list. A Pharmacy Compounding Advisory Committee (PCAC) review of nominated peptides is scheduled for July 23–24, 2026; that review will assess whether any reclassification is warranted. Removal from Category 2 is not equivalent to approval for compounding — substances must separately meet eligibility criteria under 503A or 503B
• GHRP-2 is not listed on the FDA’s 503A Category 1 eligible substances list; it is not the subject of a USP or NF monograph; and it is not a component of any FDA-approved drug product
• Compounded GHRP-2 does not currently qualify for exemptions under either Section 503A or Section 503B of the FD&C Act

WADA (Anti-Doping): GHRP-2 has been explicitly prohibited by WADA since 2008 under the category of Peptide Hormones, Growth Factors, and Related Substances — Prohibited at All Times (both in- and out-of-competition):

• GHRP-2 is listed by name on the WADA Prohibited List and has been continuously prohibited for over 15 years
• The 2026 WADA Prohibited List, effective January 1, 2026, maintains this prohibition
• Any athlete subject to anti-doping rules who uses GHRP-2 — regardless of claimed therapeutic purpose — faces a potential doping violation; no therapeutic use exemption (TUE) pathway exists for GHRP-2 given its non-approved status

Japan (PMDA): Pralmorelin is the sole jurisdiction globally where GHRP-2 has any approved clinical use — marketed by Kaken Pharmaceutical as a diagnostic agent for GH deficiency assessment via single-dose intravenous administration. This approval does not extend to therapeutic (chronic dosing) use or to subcutaneous self-administration.

International: No other regulatory authority — EMA (EU), Health Canada, TGA (Australia), or otherwise — has approved pralmorelin/GHRP-2 for any indication as of May 2026. Its availability outside Japan is currently limited to clinical trial enrollment and unregulated research chemical suppliers, the latter of which carry significant manufacturing quality and safety concerns.

GHRP-2’s safety data derives from controlled Phase 1 pharmacokinetic studies, the pediatric GHD chronic-dosing trial, Japanese diagnostic-use clinical data, and post-marketing pharmacovigilance in the Japanese diagnostic context — supplemented by the FDA’s 2023 safety review that accompanied its Category 2 listing. The overall clinical trial safety profile for short-term diagnostic dosing is favorable; long-term therapeutic safety data in the US population remains limited.

Established Adverse Effects from Clinical Trials

• Appetite stimulation and hunger: The most consistently documented acute effect beyond GH elevation; dose-dependent and robust across studies — a direct consequence of GHSR1a ghrelin-pathway agonism
• Transient cortisol and ACTH elevation: GHRP-2 reliably co-stimulates the HPA axis at therapeutic doses, producing transient cortisol increases that may be clinically significant in patients with adrenal insufficiency, diabetes, or metabolic syndrome
• Insulin sensitivity impairment: Transient decreases in insulin sensitivity have been documented — likely a combined effect of elevated GH (a counter-regulatory hormone) and cortisol co-secretion; clinically relevant in diabetic or pre-diabetic patients
• Water retention / edema: Consistent with GH-mediated effects on renal sodium retention; a class effect of GH-axis stimulation
• Flushing and mild dizziness: Reported acutely post-injection, likely reflecting GH pulse induction and cardiovascular effects of ghrelin receptor activation
• Prolactin elevation: Mild, transient prolactin co-secretion has been reported, consistent with the broad pituitary secretagogue activity of GHSR1a agonism
• Injection site reactions: Consistent with subcutaneous peptide administration; not uniquely severe relative to comparable injectable peptides

Potential Serious Adverse Effects Under FDA Review

The FDA’s September 2023 Category 2 determination specifically identified the following serious adverse events in patients who received GHRP-2 (causality not established):

• Increased insulin requirement to maintain blood glucose level — consistent with GH and cortisol-mediated insulin antagonism; clinically critical in insulin-dependent diabetics
• Death of critically ill study subjects — reported in the context of intensive care or critically ill patient populations; the clinical setting (rather than GHRP-2 specifically) complicates causality assessment, but the signal warranted Category 2 classification
• Infection — reported serious adverse event; mechanistic plausibility unclear but noted by FDA reviewers
• Pancreatitis — a serious adverse event signal; ghrelin/GHSR pathway interactions with pancreatic physiology provide potential mechanistic plausibility, though causality was not established by the FDA

Immunogenicity and Manufacturing Quality Concerns

The FDA specifically cited immunogenicity risk as a primary Category 2 safety concern for GHRP-2:

• GHRP-2’s potential for aggregation — a property of peptide-class compounds under suboptimal manufacturing conditions — creates risk of anti-peptide antibody formation (immunogenicity), which can range from loss of efficacy to serious immune reactions
• The presence of D-β-naphthylalanine (an unnatural amino acid) adds substantial complexity to API characterization, making identity, purity, and potency verification more demanding than for natural amino acid peptides — a specific concern in 503B compounding contexts where analytical resources may be limited
• For GHRP-2 obtained outside of clinical trials through research chemical or peptide vendors: no cGMP manufacturing oversight applies; contamination with residual TFA (trifluoroacetic acid), heavy metals, endotoxins, and microbial load represent serious injection safety risks; and product identity and potency cannot be verified

1. Laron Z, et al. (1998). Effects of eight months treatment with graded doses of a growth hormone-releasing peptide (GHRP-2) in prepubertal GH-deficient children. Journal of Clinical Endocrinology and Metabolism, 83(7), 2355–2358. https://doi.org/10.1210/jcem.83.7.4929
2. Kojima M, et al. (2004). Pralmorelin testing for growth hormone deficiency. Endocrine Journal, 51(3), 285–290. https://pubmed.ncbi.nlm.nih.gov/15230633/
3. Hashimoto K, et al. (2002). GH-releasing effect of GHRP-2. Clinical Endocrinology, 56(5), 595–600. https://pubmed.ncbi.nlm.nih.gov/
4. DeAlmeida VI, et al. (1997). Mechanisms of action of growth hormone-releasing peptide-2. Endocrinology, 138(10), 4419–4426. https://pubmed.ncbi.nlm.nih.gov/9331879/
5. Laferrère B, et al. (2005). Growth Hormone Releasing Peptide-2 (GHRP-2), like ghrelin, increases food intake in humans. Journal of Clinical Endocrinology and Metabolism, 90(2), 611–614. https://pmc.ncbi.nlm.nih.gov/articles/PMC2824650/
6. Bhatt S, et al. (2009). Growth hormone-releasing peptide-2 stimulates secretion of ACTH in humans. Regulatory Peptides, 158(1–3), 149–153. https://www.sciencedirect.com/science/article/abs/pii/S0167011509001669
7. Kamenický P, et al. (2009). The effect of growth hormone releasing peptide-2 on upper gastrointestinal contractile activity and food intake in conscious dogs. Journal of Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/
8. Granado M, et al. (2005). Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. American Journal of Physiology — Endocrinology and Metabolism, 288(3), E486–E492. https://pubmed.ncbi.nlm.nih.gov/
9. S. Food and Drug Administration. (2023, September 29). Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks — Category 2: GHRP-2 (for injectable and nasal routes of administration). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
10. World Anti-Doping Agency. (2025). 2026 WADA Prohibited List (effective January 1, 2026). https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
11. Amanecia Health. (2026, March 3). FDA Peptide Reclassification 2026. https://amaneciahealth.com/fda-peptide-reclassification-2026-amanecia-health/
12. DrugBank Online. (2023). Pralmorelin: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB18252